Wave Life Sciences Ltd.. (WVE) NASDAQ
$4.73 (0.08) (-1.56%)
Market Cap: $586.96M
As of 04/19/24 02:49 PM EDT. Market open.
Wave Life Sciences Ltd.. (WVE)
NASDAQ
$4.73
(0.08) (-1.56%)
Market Cap: $586.96M
As of 04/19/24 02:49 PM EDT. Market open.
Add to Portfolio
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans ... read more
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Paul Bolno
Full Time Employees
298
CEO Compensation (Base)
$541,100
CEO Compensation (Total)
$5.84M
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Paul Bolno
Full Time Employees
298
CEO Compensation (Base)
$541,100
CEO Compensation (Total)
$5.84M
Address
12 00 Marina One East Tower, 7 Straits View, 018936.
PRICE CHART FOR WAVE LIFE SCIENCES LTD.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$4.81
Previous Close
$4.80
Days Range
$4.67 - $4.84
52 week range
$3.15 - $7.67
Volume
250,578
Avg. Volume (30 days)
596,284
Market Cap
$586.96M
Dividend Yield
-
P/E
(10.21)
Shares Outstanding
122,284,139
Open
$4.81
Previous Close
$4.80
Days Range
$4.67 - $4.84
52 week range
$3.15 - $7.67
Volume
250,578
Avg. Volume (30 days)
596,284
Market Cap
$586.96M
Dividend Yield
-
P/E
(10.21)
Shares Outstanding
122,284,139
FINANCIAL STATEMENTS FOR WAVE LIFE SCIENCES LTD.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR WAVE LIFE SCIENCES LTD.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Moran Kyle | Chief Financial Officer | Apr 03, 2024 | Sale | $6.17 | 15,630 | 96,421 | 33,921 | Apr 05, 2024, 08:00 PM |
| GSK plc | 10% Owner | Dec 07, 2023 | Buy | $5.00 | 3,300,000 | 16,500,000 | 13,983,761 | Jan 30, 2024, 04:39 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Dec 11, 2023 | Buy | $5.00 | 1,000,000 | 5,000,000 | 18,202,009 | Jan 17, 2024, 07:06 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Dec 11, 2023 | Buy | $5.00 | 1,000,000 | 5,000,000 | 19,202,009 | Dec 13, 2023, 04:33 PM |
| Moran Kyle | Chief Financial Officer | Aug 23, 2023 | Sale | $4.75 | 37,062 | 176,119 | 46,120 | Aug 23, 2023, 09:15 PM |
| Vargeese Chandra | See Remarks | Feb 16, 2023 | Sale | $4.03 | 10,249 | 41,303 | 106,624 | Feb 17, 2023, 08:15 PM |
| BOLNO PAUL | President and CEO | Feb 16, 2023 | Sale | $4.04 | 29,400 | 118,776 | 407,425 | Feb 17, 2023, 08:10 PM |
| Francis Chris | See Remarks | Feb 16, 2023 | Sale | $4.03 | 10,258 | 41,340 | 79,714 | Feb 17, 2023, 08:05 PM |
| Moran Kyle | Chief Financial Officer | Feb 16, 2023 | Sale | $4.04 | 9,729 | 39,305 | 79,751 | Feb 17, 2023, 08:00 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Jun 16, 2022 | Buy | $2.15 | 9,480,052 | 20,382,113 | 17,202,009 | Jun 21, 2022, 04:33 PM |
| Vargeese Chandra | See Remarks | May 05, 2022 | Sale | $1.72 | 16,714 | 28,748 | 111,095 | May 06, 2022, 07:20 PM |
| BOLNO PAUL | President and CEO | May 05, 2022 | Sale | $1.72 | 33,501 | 57,622 | 436,825 | May 06, 2022, 07:15 PM |
| Moran Kyle | Chief Financial Officer | May 05, 2022 | Sale | $1.72 | 5,021 | 8,636 | 84,567 | May 06, 2022, 07:10 PM |
| Panzara Michael A. | See Remarks | May 05, 2022 | Sale | $1.72 | 16,714 | 28,748 | 109,103 | May 06, 2022, 07:05 PM |
| Francis Chris | See Remarks | May 05, 2022 | Sale | $1.72 | 10,867 | 18,691 | 89,972 | May 06, 2022, 07:00 PM |
| Moran Kyle | Chief Financial Officer | Feb 16, 2022 | Sale | $2.31 | 9,204 | 21,261 | 74,588 | Feb 18, 2022, 06:20 PM |
| Francis Chris | See Remarks | Feb 16, 2022 | Sale | $2.31 | 10,123 | 23,384 | 68,339 | Feb 18, 2022, 06:15 PM |
| Vargeese Chandra | Chief Technology Officer | Feb 16, 2022 | Sale | $2.32 | 10,603 | 24,599 | 77,809 | Feb 18, 2022, 06:10 PM |
| BOLNO PAUL | President and CEO | Feb 16, 2022 | Sale | $2.32 | 33,150 | 76,908 | 377,826 | Feb 18, 2022, 06:05 PM |
| Panzara Michael A. | See Remarks | Feb 16, 2022 | Sale | $2.31 | 10,603 | 24,493 | 75,817 | Feb 18, 2022, 06:00 PM |
| Moran Kyle | Chief Financial Officer | Mar 24, 2021 | Option Exercise | $2.48 | 10,930 | 27,106 | 80,792 | Mar 24, 2021, 07:45 PM |
| Francis Chris | See Remarks | Feb 16, 2021 | Sale | $10.57 | 2,698 | 28,518 | 78,462 | Feb 18, 2021, 07:26 PM |
| BOLNO PAUL | President and CEO | Feb 16, 2021 | Sale | $10.57 | 11,205 | 118,437 | 410,976 | Feb 18, 2021, 07:18 PM |
| Panzara Michael A. | See Remarks | Feb 16, 2021 | Sale | $10.57 | 2,929 | 30,960 | 86,420 | Feb 18, 2021, 07:16 PM |
| Vargeese Chandra | Chief Technology Officer | Feb 16, 2021 | Sale | $10.57 | 3,145 | 33,243 | 85,412 | Feb 18, 2021, 07:14 PM |
| Moran Kyle | Chief Financial Officer | Feb 16, 2021 | Sale | $10.57 | 1,722 | 18,202 | 69,862 | Feb 18, 2021, 07:09 PM |
| BOLNO PAUL | President and CEO | Sep 15, 2020 | Option Exercise | $2.48 | 100,000 | 248,000 | 372,181 | Sep 17, 2020, 09:10 PM |
| BOLNO PAUL | President and CEO | Sep 15, 2020 | Sale | $15.00 | 100,000 | 1,500,000 | 272,181 | Sep 17, 2020, 09:10 PM |
| BOLNO PAUL | President and CEO | Aug 25, 2020 | Option Exercise | $2.48 | 25,000 | 62,000 | 297,181 | Aug 27, 2020, 06:44 PM |
| BOLNO PAUL | President and CEO | Aug 25, 2020 | Sale | $12.00 | 25,000 | 300,000 | 272,181 | Aug 27, 2020, 06:44 PM |
| BOLNO PAUL | President and CEO | Jul 02, 2020 | Option Exercise | $2.48 | 100,000 | 248,000 | 372,181 | Jul 02, 2020, 08:56 PM |
| BOLNO PAUL | President and CEO | Jul 02, 2020 | Sale | $10.30 | 147,577 | 1,520,276 | 368,102 | Jul 02, 2020, 08:56 PM |
| Panzara Michael A. | Chief Medical Officer | Feb 18, 2020 | Sale | $7.85 | 2,981 | 23,401 | 39,349 | Feb 20, 2020, 06:26 PM |
| BOLNO PAUL | President and CEO | Feb 18, 2020 | Sale | $7.85 | 11,451 | 89,890 | 319,758 | Feb 20, 2020, 06:23 PM |
| Francis Chris | See Remarks | Feb 18, 2020 | Sale | $7.85 | 2,708 | 21,258 | 31,160 | Feb 20, 2020, 06:21 PM |
| Vargeese Chandra | Senior VP, Drug Discovery | Feb 18, 2020 | Sale | $7.85 | 3,188 | 25,026 | 37,057 | Feb 20, 2020, 06:18 PM |
| Gaiero David G | Interim CFO | Feb 03, 2020 | Sale | $7.00 | 651 | 4,557 | 6,392 | Feb 05, 2020, 06:16 PM |
| Vargeese Chandra | Senior VP, Drug Discovery | Dec 03, 2019 | Option Exercise | $2.48 | 6,000 | 14,880 | 46,245 | Dec 05, 2019, 06:08 PM |
| Vargeese Chandra | Senior VP, Drug Discovery | Dec 03, 2019 | Sale | $35.00 | 6,000 | 210,000 | 40,245 | Dec 05, 2019, 06:08 PM |
| Verdine Gregory L. | Director | Nov 20, 2019 | Sale | $30.63 | 30,039 | 920,213 | 36,009 | Nov 22, 2019, 05:49 PM |
| Panzara Michael A. | Chief Medical Officer | Jul 05, 2019 | Sale | $26.94 | 3,058 | 82,368 | 42,775 | Jul 09, 2019, 06:11 PM |
| BOLNO PAUL | President and CEO | Mar 15, 2019 | Option Exercise | $2.48 | 50,000 | 124,000 | 381,209 | Mar 19, 2019, 06:44 PM |
| BOLNO PAUL | President and CEO | Mar 15, 2019 | Sale | $45.48 | 50,000 | 2,273,804 | 346,274 | Mar 19, 2019, 06:44 PM |
| Panzara Michael A. | Franchise Lead, Neurology | Mar 11, 2019 | Sale | $48.00 | 7,000 | 336,000 | 45,388 | Mar 11, 2019, 07:18 PM |
| Regnante Keith | Chief Financial Officer | Feb 19, 2019 | Sale | $36.84 | 1,298 | 47,818 | 15,686 | Feb 21, 2019, 07:54 PM |
| Panzara Michael A. | Franchise Lead, Neurology | Feb 19, 2019 | Sale | $36.84 | 1,837 | 67,674 | 37,388 | Feb 21, 2019, 07:53 PM |
| BOLNO PAUL | President and CEO | Feb 19, 2019 | Sale | $36.40 | 7,733 | 281,456 | 271,328 | Feb 21, 2019, 07:51 PM |
| Vargeese Chandra | Senior VP, Drug Discovery | Feb 19, 2019 | Sale | $36.84 | 2,055 | 75,706 | 25,245 | Feb 21, 2019, 07:49 PM |
| Francis Chris | See Remarks | Feb 19, 2019 | Sale | $36.84 | 1,709 | 62,959 | 20,368 | Feb 21, 2019, 07:47 PM |
| RA CAPITAL MANAGEMENT, LLC | Director | Jan 24, 2019 | Buy | $38.00 | 263,158 | 10,000,004 | 7,775,207 | Jan 28, 2019, 04:33 PM |
| Verdine Gregory L. | Director | Nov 14, 2018 | Sale | $38.86 | 15,000 | 582,849 | 64,339 | Nov 16, 2018, 05:15 PM |
| Francis Chris | See Remarks | Sep 25, 2018 | Option Exercise | $2.48 | 10,543 | 26,147 | 32,620 | Sep 26, 2018, 07:01 PM |
| Francis Chris | See Remarks | Sep 24, 2018 | Option Exercise | $2.48 | 1,032 | 2,559 | 23,109 | Sep 26, 2018, 07:01 PM |
| Francis Chris | See Remarks | Sep 25, 2018 | Sale | $56.00 | 10,543 | 590,408 | 22,077 | Sep 26, 2018, 07:01 PM |
| Francis Chris | See Remarks | Sep 24, 2018 | Sale | $56.00 | 1,032 | 57,792 | 22,077 | Sep 26, 2018, 07:01 PM |
| Regnante Keith | Chief Financial Officer | Sep 24, 2018 | Option Exercise | $20.89 | 29,500 | 616,255 | 46,484 | Sep 26, 2018, 06:59 PM |
| Regnante Keith | Chief Financial Officer | Sep 24, 2018 | Sale | $55.00 | 29,500 | 1,622,500 | 16,984 | Sep 26, 2018, 06:59 PM |
| Vargeese Chandra | Senior VP, Drug Discovery | Sep 24, 2018 | Option Exercise | $2.48 | 3,000 | 7,440 | 30,300 | Sep 26, 2018, 06:58 PM |
| Vargeese Chandra | Senior VP, Drug Discovery | Sep 24, 2018 | Sale | $55.00 | 3,000 | 165,000 | 27,300 | Sep 26, 2018, 06:58 PM |
| Francis Chris | See Remarks | Jul 09, 2018 | Option Exercise | $2.48 | 24,496 | 60,750 | 45,977 | Jul 11, 2018, 05:05 PM |
| Francis Chris | See Remarks | Jul 09, 2018 | Sale | $37.27 | 24,496 | 913,054 | 22,077 | Jul 11, 2018, 05:05 PM |
| Francis Chris | See Remarks | Jun 01, 2018 | Option Exercise | $2.48 | 24,496 | 60,750 | 46,573 | Jun 01, 2018, 06:29 PM |
| Francis Chris | See Remarks | May 30, 2018 | Option Exercise | $2.48 | 24,496 | 60,750 | 46,573 | Jun 01, 2018, 06:29 PM |
| Francis Chris | See Remarks | Jun 01, 2018 | Sale | $48.00 | 24,496 | 1,175,808 | 22,077 | Jun 01, 2018, 06:29 PM |
| Francis Chris | See Remarks | May 30, 2018 | Sale | $45.50 | 24,496 | 1,114,568 | 22,077 | Jun 01, 2018, 06:29 PM |
| BOLNO PAUL | President and CEO | May 29, 2018 | Option Exercise | $2.48 | 3,145 | 7,800 | 282,087 | May 30, 2018, 09:18 PM |
| BOLNO PAUL | President and CEO | May 25, 2018 | Option Exercise | $2.48 | 8,316 | 20,624 | 287,258 | May 30, 2018, 09:18 PM |
| BOLNO PAUL | President and CEO | May 30, 2018 | Option Exercise | $2.48 | 20,250 | 50,220 | 299,192 | May 30, 2018, 09:18 PM |
| BOLNO PAUL | President and CEO | May 29, 2018 | Sale | $45.00 | 3,145 | 141,525 | 278,942 | May 30, 2018, 09:18 PM |
| BOLNO PAUL | President and CEO | May 25, 2018 | Sale | $45.00 | 8,316 | 374,220 | 278,942 | May 30, 2018, 09:18 PM |
| BOLNO PAUL | President and CEO | May 30, 2018 | Sale | $45.00 | 20,250 | 911,250 | 278,942 | May 30, 2018, 09:18 PM |
| BOLNO PAUL | President and CEO | May 02, 2018 | Option Exercise | $2.48 | 18,289 | 45,357 | 297,231 | May 04, 2018, 08:04 PM |
| BOLNO PAUL | President and CEO | May 02, 2018 | Sale | $45.00 | 18,289 | 823,005 | 278,942 | May 04, 2018, 08:04 PM |
| Francis Chris | See Remarks | Feb 20, 2018 | Option Exercise | $2.48 | 11,504 | 28,530 | 33,581 | Feb 21, 2018, 07:19 PM |
| Francis Chris | See Remarks | Feb 16, 2018 | Option Exercise | $2.48 | 9,412 | 23,342 | 31,489 | Feb 21, 2018, 07:19 PM |
| Francis Chris | See Remarks | Feb 20, 2018 | Sale | $55.95 | 11,504 | 643,649 | 22,077 | Feb 21, 2018, 07:19 PM |
| Francis Chris | See Remarks | Feb 16, 2018 | Sale | $54.77 | 10,135 | 555,111 | 22,077 | Feb 21, 2018, 07:19 PM |
| BOLNO PAUL | President and CEO | Feb 16, 2018 | Sale | $51.50 | 2,714 | 139,783 | 281,142 | Feb 21, 2018, 07:18 PM |
| Panzara Michael A. | Franchise Lead, Neurology | Feb 16, 2018 | Sale | $52.10 | 511 | 26,623 | 39,225 | Feb 21, 2018, 07:17 PM |
| Regnante Keith | Chief Financial Officer | Feb 16, 2018 | Sale | $51.85 | 316 | 16,385 | 16,984 | Feb 21, 2018, 07:16 PM |
| Vargeese Chandra | See Remarks | Feb 15, 2018 | Option Exercise | $2.48 | 2,000 | 4,960 | 29,300 | Feb 20, 2018, 07:36 PM |
| Vargeese Chandra | See Remarks | Feb 15, 2018 | Sale | $50.00 | 2,000 | 100,000 | 27,300 | Feb 20, 2018, 07:36 PM |
| Panzara Michael A. | Franchise Lead, Neurology | Feb 15, 2018 | Option Exercise | $21.69 | 18,750 | 406,688 | 58,486 | Feb 20, 2018, 07:34 PM |
| Panzara Michael A. | Franchise Lead, Neurology | Feb 15, 2018 | Sale | $50.00 | 18,750 | 937,500 | 39,736 | Feb 20, 2018, 07:34 PM |
| Vargeese Chandra | See Remarks | Jan 23, 2018 | Option Exercise | $2.48 | 2,000 | 4,960 | 11,800 | Jan 25, 2018, 08:12 PM |
| Vargeese Chandra | See Remarks | Jan 23, 2018 | Sale | $40.00 | 2,000 | 80,000 | 9,800 | Jan 25, 2018, 08:12 PM |
| Vargeese Chandra | See Remarks | Nov 22, 2017 | Option Exercise | $2.48 | 1,500 | 3,720 | 1,500 | Nov 22, 2017, 09:28 PM |
| Vargeese Chandra | See Remarks | Nov 22, 2017 | Sale | $35.00 | 1,500 | 52,500 | 0 | Nov 22, 2017, 09:28 PM |
| RA CAPITAL MANAGEMENT, LLC | Director | Nov 14, 2017 | Buy | $24.00 | 23,398 | 561,550 | 7,512,049 | Nov 15, 2017, 04:35 PM |
| RA CAPITAL MANAGEMENT, LLC | Director | Nov 13, 2017 | Buy | $23.30 | 400,000 | 9,320,000 | 7,488,651 | Nov 15, 2017, 04:35 PM |
| Tanaka Masaharu | Director | Sep 18, 2017 | Sale | $24.19 | 6,362 | 153,897 | 2,774,118 | Sep 19, 2017, 09:09 PM |
| Tanaka Masaharu | Director | Sep 15, 2017 | Sale | $24.22 | 14,385 | 348,405 | 2,780,480 | Sep 19, 2017, 09:09 PM |
| Panzara Michael A. | Franchise Lead, Neurology | Jul 12, 2017 | Sale | $16.67 | 7,414 | 123,620 | 15,336 | Jul 13, 2017, 05:09 PM |
| Tanaka Masaharu | Director | Mar 29, 2017 | Sale | $24.91 | 433,825 | 10,806,581 | 2,794,865 | Mar 31, 2017, 03:34 PM |
| GUERCIOLINI ROBERTO | See Remarks | Dec 07, 2016 | Option Exercise | $2.47 | 24,000 | 59,280 | 20,000 | Dec 09, 2016, 06:36 PM |
| GUERCIOLINI ROBERTO | See Remarks | Aug 19, 2016 | Option Exercise | $2.47 | 5,000 | 12,350 | 5,000 | Aug 22, 2016, 04:12 PM |
| GUERCIOLINI ROBERTO | See Remarks | Jul 28, 2016 | Option Exercise | $2.47 | 5,000 | 12,350 | 5,000 | Jul 29, 2016, 04:41 PM |
| Verdine Gregory L. | Director | Jun 15, 2016 | Sale | $16.70 | 52,000 | 868,400 | 150,079 | Jun 17, 2016, 05:02 PM |
| TAKANASHI KEN | Director | Nov 16, 2015 | Buy | $16.00 | 125,000 | 2,000,000 | 1,984,130 | Nov 18, 2015, 07:55 PM |
| Tanaka Masaharu | Director | Nov 16, 2015 | Buy | $16.00 | 76,250 | 1,220,000 | 3,228,690 | Nov 18, 2015, 07:29 PM |
| RA CAPITAL MANAGEMENT, LLC | Director | Nov 16, 2015 | Buy | $16.00 | 1,875,000 | 30,000,000 | 7,088,651 | Nov 18, 2015, 05:30 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Moran Kyle | Chief Financial Officer | 04/03/2024 | 96,421 |
| GSK plc | 10% Owner | 12/07/2023 | 16,500,000 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 12/11/2023 | 5,000,000 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 12/11/2023 | 5,000,000 |
| Moran Kyle | Chief Financial Officer | 08/23/2023 | 176,119 |
| Vargeese Chandra | See Remarks | 02/16/2023 | 41,303 |
| BOLNO PAUL | President and CEO | 02/16/2023 | 118,776 |
| Francis Chris | See Remarks | 02/16/2023 | 41,340 |
| Moran Kyle | Chief Financial Officer | 02/16/2023 | 39,305 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 06/16/2022 | 20,382,113 |
| Vargeese Chandra | See Remarks | 05/05/2022 | 28,748 |
| BOLNO PAUL | President and CEO | 05/05/2022 | 57,622 |
| Moran Kyle | Chief Financial Officer | 05/05/2022 | 8,636 |
| Panzara Michael A. | See Remarks | 05/05/2022 | 28,748 |
| Francis Chris | See Remarks | 05/05/2022 | 18,691 |
| Moran Kyle | Chief Financial Officer | 02/16/2022 | 21,261 |
| Francis Chris | See Remarks | 02/16/2022 | 23,384 |
| Vargeese Chandra | Chief Technology Officer | 02/16/2022 | 24,599 |
| BOLNO PAUL | President and CEO | 02/16/2022 | 76,908 |
| Panzara Michael A. | See Remarks | 02/16/2022 | 24,493 |
| Moran Kyle | Chief Financial Officer | 03/24/2021 | 27,106 |
| Francis Chris | See Remarks | 02/16/2021 | 28,518 |
| BOLNO PAUL | President and CEO | 02/16/2021 | 118,437 |
| Panzara Michael A. | See Remarks | 02/16/2021 | 30,960 |
| Vargeese Chandra | Chief Technology Officer | 02/16/2021 | 33,243 |
| Moran Kyle | Chief Financial Officer | 02/16/2021 | 18,202 |
| BOLNO PAUL | President and CEO | 09/15/2020 | 248,000 |
| BOLNO PAUL | President and CEO | 09/15/2020 | 1,500,000 |
| BOLNO PAUL | President and CEO | 08/25/2020 | 62,000 |
| BOLNO PAUL | President and CEO | 08/25/2020 | 300,000 |
| BOLNO PAUL | President and CEO | 07/02/2020 | 248,000 |
| BOLNO PAUL | President and CEO | 07/02/2020 | 1,520,276 |
| Panzara Michael A. | Chief Medical Officer | 02/18/2020 | 23,401 |
| BOLNO PAUL | President and CEO | 02/18/2020 | 89,890 |
| Francis Chris | See Remarks | 02/18/2020 | 21,258 |
| Vargeese Chandra | Senior VP, Drug Discovery | 02/18/2020 | 25,026 |
| Gaiero David G | Interim CFO | 02/03/2020 | 4,557 |
| Vargeese Chandra | Senior VP, Drug Discovery | 12/03/2019 | 14,880 |
| Vargeese Chandra | Senior VP, Drug Discovery | 12/03/2019 | 210,000 |
| Verdine Gregory L. | Director | 11/20/2019 | 920,213 |
| Panzara Michael A. | Chief Medical Officer | 07/05/2019 | 82,368 |
| BOLNO PAUL | President and CEO | 03/15/2019 | 124,000 |
| BOLNO PAUL | President and CEO | 03/15/2019 | 2,273,804 |
| Panzara Michael A. | Franchise Lead, Neurology | 03/11/2019 | 336,000 |
| Regnante Keith | Chief Financial Officer | 02/19/2019 | 47,818 |
| Panzara Michael A. | Franchise Lead, Neurology | 02/19/2019 | 67,674 |
| BOLNO PAUL | President and CEO | 02/19/2019 | 281,456 |
| Vargeese Chandra | Senior VP, Drug Discovery | 02/19/2019 | 75,706 |
| Francis Chris | See Remarks | 02/19/2019 | 62,959 |
| RA CAPITAL MANAGEMENT, LLC | Director | 01/24/2019 | 10,000,004 |
| Verdine Gregory L. | Director | 11/14/2018 | 582,849 |
| Francis Chris | See Remarks | 09/25/2018 | 26,147 |
| Francis Chris | See Remarks | 09/24/2018 | 2,559 |
| Francis Chris | See Remarks | 09/25/2018 | 590,408 |
| Francis Chris | See Remarks | 09/24/2018 | 57,792 |
| Regnante Keith | Chief Financial Officer | 09/24/2018 | 616,255 |
| Regnante Keith | Chief Financial Officer | 09/24/2018 | 1,622,500 |
| Vargeese Chandra | Senior VP, Drug Discovery | 09/24/2018 | 7,440 |
| Vargeese Chandra | Senior VP, Drug Discovery | 09/24/2018 | 165,000 |
| Francis Chris | See Remarks | 07/09/2018 | 60,750 |
| Francis Chris | See Remarks | 07/09/2018 | 913,054 |
| Francis Chris | See Remarks | 06/01/2018 | 60,750 |
| Francis Chris | See Remarks | 05/30/2018 | 60,750 |
| Francis Chris | See Remarks | 06/01/2018 | 1,175,808 |
| Francis Chris | See Remarks | 05/30/2018 | 1,114,568 |
| BOLNO PAUL | President and CEO | 05/29/2018 | 7,800 |
| BOLNO PAUL | President and CEO | 05/25/2018 | 20,624 |
| BOLNO PAUL | President and CEO | 05/30/2018 | 50,220 |
| BOLNO PAUL | President and CEO | 05/29/2018 | 141,525 |
| BOLNO PAUL | President and CEO | 05/25/2018 | 374,220 |
| BOLNO PAUL | President and CEO | 05/30/2018 | 911,250 |
| BOLNO PAUL | President and CEO | 05/02/2018 | 45,357 |
| BOLNO PAUL | President and CEO | 05/02/2018 | 823,005 |
| Francis Chris | See Remarks | 02/20/2018 | 28,530 |
| Francis Chris | See Remarks | 02/16/2018 | 23,342 |
| Francis Chris | See Remarks | 02/20/2018 | 643,649 |
| Francis Chris | See Remarks | 02/16/2018 | 555,111 |
| BOLNO PAUL | President and CEO | 02/16/2018 | 139,783 |
| Panzara Michael A. | Franchise Lead, Neurology | 02/16/2018 | 26,623 |
| Regnante Keith | Chief Financial Officer | 02/16/2018 | 16,385 |
| Vargeese Chandra | See Remarks | 02/15/2018 | 4,960 |
| Vargeese Chandra | See Remarks | 02/15/2018 | 100,000 |
| Panzara Michael A. | Franchise Lead, Neurology | 02/15/2018 | 406,688 |
| Panzara Michael A. | Franchise Lead, Neurology | 02/15/2018 | 937,500 |
| Vargeese Chandra | See Remarks | 01/23/2018 | 4,960 |
| Vargeese Chandra | See Remarks | 01/23/2018 | 80,000 |
| Vargeese Chandra | See Remarks | 11/22/2017 | 3,720 |
| Vargeese Chandra | See Remarks | 11/22/2017 | 52,500 |
| RA CAPITAL MANAGEMENT, LLC | Director | 11/14/2017 | 561,550 |
| RA CAPITAL MANAGEMENT, LLC | Director | 11/13/2017 | 9,320,000 |
| Tanaka Masaharu | Director | 09/18/2017 | 153,897 |
| Tanaka Masaharu | Director | 09/15/2017 | 348,405 |
| Panzara Michael A. | Franchise Lead, Neurology | 07/12/2017 | 123,620 |
| Tanaka Masaharu | Director | 03/29/2017 | 10,806,581 |
| GUERCIOLINI ROBERTO | See Remarks | 12/07/2016 | 59,280 |
| GUERCIOLINI ROBERTO | See Remarks | 08/19/2016 | 12,350 |
| GUERCIOLINI ROBERTO | See Remarks | 07/28/2016 | 12,350 |
| Verdine Gregory L. | Director | 06/15/2016 | 868,400 |
| TAKANASHI KEN | Director | 11/16/2015 | 2,000,000 |
| Tanaka Masaharu | Director | 11/16/2015 | 1,220,000 |
| RA CAPITAL MANAGEMENT, LLC | Director | 11/16/2015 | 30,000,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN WAVE LIFE SCIENCES LTD.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 18,202,009 | 1.44% | 5.81% | Other |
| MAVERICK CAPITAL LTD | 8,447,804 | 0.86% | 28.11% | Growth At A Reasonable Price, Growth |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,987,730 | 0.06% | 58.08% | Other |
| BLACKROCK INC. | 5,366,288 | 0.00069% | 10.33% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,459,764 | 0.00077% | 4.63% | Other |
| PLATINUM INVESTMENT MANAGEMENT LTD | 655,331 | 0.13% | 43.92% | Growth At A Reasonable Price, Value |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 587,575 | 0.04% | New | Growth |
| BALYASNY ASSET MANAGEMENT L.P. | 88,970 | 0.00084% | 144.75% | Event Driven |
| TUDOR INVESTMENT CORP ET AL | 36,580 | 0.00149% | New | Event Driven, Other |
| RENAISSANCE TECHNOLOGIES LLC | 14,700 | 0.00011% | -53.63% | Other |
| AQR CAPITAL MANAGEMENT LLC | 11,168 | 0.00011% | 0.86% | Other |
CHANGE IN SHARES OUTSTANDING FOR WAVE LIFE SCIENCES LTD.
STOCK BUYBACKS FOR WAVE LIFE SCIENCES LTD.
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
3.58%
1Q
06/30/2023
5.06%
2Q
03/31/2023
8.57%
3Q
12/31/2022
17.67%
4Q
09/30/2022
18.00%
5Q
06/30/2022
66.67%
6Q
03/31/2022
83.09%
7Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR WAVE LIFE SCIENCES LTD.
LOADING...